After her hypoparathyroidism diagnosis, columnist Bari Vapnek was just going through the motions. Now, she's committed to living fully.
Imagine waking up each morning not knowing how you will feel that day. Welcome to my life with hypoparathyroidism! Following my diagnosis, I was lucky to have a husband who took care of me, which ...
Canada’s Drug Agency (CDA-AMC) is urging that Yorvipath (palopegteriparatide) — an injection therapy approved in the country earlier this year — be reimbursed for eligible adults with hard-to-treat ...
It’s easy to get lost in the fun of summer, especially when on vacation. This was extra true for me when it came time for my annual trip with my lifelong best friends. Having missed last year due to ...
Hypoparathyroidism treatments aim to normalize the body’s calcium levels, as most symptoms of the disease arise due to calcium deficiency, and improve quality of life. Standard treatment typically ...
People with chronic hypoparathyroidism who are treated by endocrinologists — doctors who specialize in hormone-related diseases — are more likely to achieve recommended blood levels of calcium and ...
Daily treatment with Yorvipath (palopegteriparatide) leads to rapid and sustained improvement in kidney function among adults with hypoparathyroidism, according to newly published data from the ...
Treatment for at least three years with Yorvipath (palopegteriparatide), an approved daily hormone replacement therapy used to help manage blood calcium levels in adults with hypoparathyroidism, led ...
Men with chronic hypoparathyroidism may be more likely to develop chronic kidney disease (CKD), while women with the disorder may face higher risks of bone fractures, anxiety, and cognitive problems, ...
Single doses of canvuparatide, an injectable hormone replacement treatment being developed by MBX Biosciences for chronic hypoparathyroidism, appeared to be safe in healthy adults and were long-acting ...
I’m often asked by fellow hypoparathyroidism patients how they can get an at-home calcium tester, and I’ve always had to explain that there wasn’t an option — until now. Finally, one is in development ...